Intralymphatic injection of aluminum-formulated glutamic acid decarboxylase (GAD-alum) delays the progression of T1D with immunomodulatory effects including increased PD-1+ CD69+ cells in both CD8+ and double negative T cells (109, 110). Here, CD69 is linked to type 1 diabetes mellitus.